OncLive

2 days ago | onclive.com | Ashling Wahner

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancers (NSCLC) have added taletrectinib (Ibtrozi) as a preferred agent for the first-line and subsequent treatment of patients with advanced ROS1-positive NSCLC.1,2The guidelines also include recommendations for the use of taletrectinib—a highly selective, next-generation oral ROS1 TKI—in patients with brain metastases and resistance mutations.

2 days ago | onclive.com | Ashling Wahner

The neoadjuvant combination of pembrolizumab (Keytruda) with the TLR9 agonist vidutolimod (formerly CMP-001) generated higher pathologic complete response (pCR) rates vs pembrolizumab alone, as well as an acceptable safety profile, in patients with macroscopic, resectable stage III melanoma, according to Ahmad Tarhini, MD, PhD.

1 week ago | onclive.com | Kristi Rosa

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous formulation of daratumumab (daratumumab and hyaluronidase-fihj; Darzalex Faspro) for use as a single agent in adult patients with smoldering multiple myeloma that is at high risk of developing multiple myeloma.1 The recommendation is supported by findings from the phase 3 AQUILA study (NCT03301220), which showed that at a median follow-up of 65.2 months (range,...

1 week ago | onclive.com | Ashley Chan

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of UM171 cell therapy (Zemcelpro) for the treatment of adult patients with hematological malignancies who require allogeneic hematopoietic stem cell transplantation after myeloablative conditioning and who do not have other suitable donor cells available.1 Notably, the European Commission is expected to announce its final decision within...

1 week ago | onclive.com | Ashley Chan

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion for cabozantinib (Cabometyx) for the treatment of adult patients with unresectable or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET) and pancreatic neuroendocrine tumors (pNET) who have progressed after at least 1 prior systemic therapy besides somatostatin analogues.1 The CHMP’s recommendation is based on data from the phase 3 CABINET trial...